Multiple prior studies have implicated Endocan in modulating cell proliferation, migration, and invasion in renal, colorectal, non-small cell lung, and hepatocellular cancers10, and showed that its expression correlated with poor prognosis in GBM patients7. The gene discussed is ESM1; the disease is glioblastoma.